4.46
0.19 (4.45%)
| Penutupan Terdahulu | 4.27 |
| Buka | 4.34 |
| Jumlah Dagangan | 91,594 |
| Purata Dagangan (3B) | 241,291 |
| Modal Pasaran | 1,583,777,280 |
| Harga / Pendapatan (P/E Ke hadapan) | 59.88 |
| Harga / Jualan (P/S) | 2.00 |
| Harga / Buku (P/B) | 1.60 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2024 |
| Margin Keuntungan | -22.05% |
| Margin Operasi (TTM) | -17.68% |
| EPS Cair (TTM) | -0.500 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -5.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 48.54% |
| Nisbah Semasa (MRQ) | 2.09 |
| Aliran Tunai Operasi (OCF TTM) | -36.05 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -188.42 M |
| Pulangan Atas Aset (ROA TTM) | -1.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Evotec SE | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.75 |
|
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Institusi | 2.37% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Dcf Advisers, Llc | 30 Sep 2024 | 217,055 |
| Mediolanum International Funds Ltd | 30 Sep 2024 | 140,383 |
| Clear Harbor Asset Management, Llc | 30 Sep 2024 | 28,600 |
| Briaud Financial Planning, Inc | 30 Sep 2024 | 2,160 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 8.00 (HC Wainwright & Co., 79.37%) | Beli |
| Median | 5.90 (32.29%) | |
| Rendah | 3.80 (Jefferies, -14.80%) | Pegang |
| Purata | 5.90 (32.29%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 3.80 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Nov 2024 | 8.00 (79.37%) | Beli | 4.25 |
| Jefferies | 07 Oct 2024 | 3.80 (-14.80%) | Pegang | 3.34 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |